The Oxford Science Park

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Physiomics & Beyond Blood announce collaboration

28 Mar 2023

Physiomics & Beyond Blood announce collaboration Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has signed an agreement with Beyond Blood Diagnostics Ltd (“Beyond Blood”) (https://beyondblood.co) to analyse data generated during testing of its diagnostic platform using Physiomics’... Read more

Oxford Cancer Biomarkers granted Artificial Intelligence in Health and Care Award

03 Mar 2023

OXFORD, UK – 3rd March 2023 – Oxford Cancer Biomarkers Ltd (OCB) announces today the receipt of an important AI award from the NHS AI Lab (joint unit of teams from the Department of Health and Social Care and NHS England and NHS Improvement). Fundings will be deployed to support a large UK clinical trial aimed at evaluating the clinical utility of the company’s OncoProg® test, a digital pathology solution that uses a sophisticated image... Read more

Planning approval for three major new buildings at TOSP is significant for Oxford life sciences sector

02 Mar 2023

Planning approval for three major new buildings at TOSP is significant for Oxford life sciences sector Plots 23-26 to provide 400,000 sq ft of lab & office facilities Oxford, UK, March 2 2023 – Planning approval has been granted for three new state-of-the-art laboratory and office buildings on The Oxford Science Park (TOSP), one of Europe's leading locations for science and technology companies. The 400,000 sq ft scheme, the first stage of... Read more

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

02 Feb 2023

- EXS4318 is the first immunology & inflammation candidate designed by Exscientia and its fourth molecule to enter the clinic - - Exscientia invented a potentially first-in-class potent and selective PKC theta inhibitor - - Eligible for pre-commercial milestone payments and, if approved, tiered royalties on net product sales - OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a... Read more

BERGENBIO ANNOUNCES THE ESTABLISHMENT OF ONCOLOGY SCIENTIFIC ADVISORY BOARD